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Lipidomic analysis reveals 
sphingomyelin and 
phosphatidylcholine species 
associated with renal impairment 
and all-cause mortality in type 1 
diabetes
nete tofte  1,3*, Tommi Suvitaival1,3, Linda Ahonen  1, Signe A. Winther1, Simone theilade1, 
Marie frimodt-Møller1, Tarunveer S. Ahluwalia1,4 & peter Rossing  1,2,4
there is an urgent need for a better molecular understanding of the pathophysiology underlying 
development and progression of diabetic nephropathy. The aim of the current study was to identify 
novel associations between serum lipidomics and diabetic nephropathy. Non-targeted serum lipidomic 
analyses were performed with mass spectrometry in 669 individuals with type 1 diabetes. Cross-
sectional associations of lipid species with estimated glomerular filtration rate (eGFR) and urinary 
albumin excretion were assessed. Moreover, associations with register-based longitudinal follow-up 
for progression to a combined renal endpoint including ≥30% decline in eGFR, ESRD and all-cause 
mortality were evaluated. Median follow-up time was 5.0–6.4 years. Adjustments included traditional 
risk factors and multiple testing correction. In total, 106 lipid species were identified. Primarily, alkyl-
acyl phosphatidylcholines, triglycerides and sphingomyelins demonstrated cross-sectional associations 
with eGFR and macroalbuminuria. In longitudinal analyses, thirteen lipid species were associated with 
the slope of eGFR or albuminuria. Of these lipids, phosphatidylcholine and sphingomyelin species, 
PC(O-34:2), PC(O-34:3), SM(d18:1/24:0), SM(d40:1) and SM(d41:1), were associated with lower risk of 
the combined renal endpoint. PC(O-34:3), SM(d40:1) and SM(d41:1) were associated with lower risk 
of all-cause mortality while an SM(d18:1/24:0) was associated with lower risk of albuminuria group 
progression. We report distinct associations between lipid species and risk of renal outcomes in type 1 
diabetes, independent of traditional markers of kidney function.
In current clinical practice eGFR and urinary albumin excretion rate (UAER) are measured as markers of renal 
status in diabetic nephropathy (DN). These biomarkers are strong predictors of progression in DN1, although 
neither is necessarily altered at the early stages of disease. Hence, there is a need to identify potential metabolites 
and novel pathways underlying development and progression of DN and/or future therapeutic targets.
In recent years, new omics-based techniques have emerged and allowed for the study of complex metabolic 
pathways. Lipidomics enables the comprehensive investigation and analysis of the lipid species present in biolog-
ical systems2. Both intracellular and circulating lipids have been hypothesized to play a role in the pathogenesis 
of both diabetic and non-diabetic kidney disease3,4. In a review of basic animal and human studies, the evidence 
pointed towards intracellular sphingolipid accumulation in the glomeruli as a causal factor for glomerular pro-
liferation and hypertrophy in DN5. In line with this, a study applying genome-wide transcriptome analyses on 
normal and fibrotic human kidney tubule samples demonstrated that fibrotic kidneys had lower expression of 
regulators of fatty acid oxidation and higher intracellular lipid deposition compared to normal kidneys6. In Fabry 
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disease, a proteinuric kidney disease of genetic origin, targeting sphingolipid metabolism by enzyme replacement 
therapy has previously been demonstrated to ameliorate disease progression7, however, less is known about tar-
geting the sphingolipid metabolism in non-genetic kidney diseases, for example DN.
Recent studies on serum/plasma lipidomics and diabetic kidney disease, in individuals with type 1 diabetes8–10 
or type 2 diabetes11–16, have primarily examined cross sectional or longitudinal associations only with albuminu-
ria status.
To our knowledge, the relation between blood lipidomics and development of end stage renal disease (ESRD) 
or mortality has never been examined in individuals with type 1 diabetes. This study measures serum lipidomic 
profiles in persons with type 1 diabetes and examines their cross-sectional association with eGFR and albuminu-
ria. Further, this study has the advantage of also investigating the association of lipids identified in cross-sectional 
analyses, to longitudinal outcomes of renal impairment, ESRD and all-cause mortality.
Results
The study included 669 Caucasian individuals with type 1 diabetes with a mean age of 55 ± 13 years, a median 
diabetes duration of 35 [24–44] years and 45% women (Table 1). Overall, 47% had persistent normoalbuminuria 
at baseline, 25% and 28% had a history of or current microalbuminuria and macroalbuminuria, respectively. 
At baseline mean eGFR was 81 ± 26 ml min−1 1.73 m−2 and median UAER was 18 [8–64] mg/24-h. Number of 
individuals in each eGFR category (in ml min−1 1.73 m−2) were as follows: <15 (n = 2), 15–29 (n = 23), 30–44 
(n = 50), 45–59 (n = 72), 60–74 (n = 83), 75–89 (n = 161) and >90 (n = 275), for three individuals eGFR at base-
line was missing. During follow-up, 37 individuals progressed in albuminuria status, 93 participants experienced 
a decline in eGFR ≥ 30%, 21 individuals developed ESRD, 58 died and 125 had at least one event in the combined 
renal endpoint. Median follow-up time was 5.8 [2.5–6.4] years for assessment of albuminuria progression, 5.3 
[2.7–6.2] years for ≥30% decline in eGFR, 5.3 [4.8–5.7] years for development of ESRD and 6.2 [5.8–6.7] years 
for all-cause mortality. The eGFR and UACR slopes were based on medians of 6 measurements in 516 participants 
and 17 measurements in 517 participants, respectively. The mean yearly change in eGFR was -0.9 ± 2.5 ml/min/
year and the median yearly change in UACR was 3.5 [-13.0–8.7] %.
All participants 
(n = 669)
Normoalbuminuria 
(n = 312)
Microalbuminuria 
(n = 168)
Macroalbuminuria 
(n = 189)
Normo- vs. micro- vs. 
macro-albuminuria p
Female, n (%) 299 (45) 155 (50) 62 (37) 81 (43) 0.031
Age, years 55 ± 13 53 ± 14 58 ± 13 55 ± 10 <0.001
Diabetes duration, years 35 [24–44] 30 [9–41] 36 [26–48] 39 [31–45] <0.001
Body mass index, kg/m2 26 ± 6 25 ± 4 26 ± 4 26 ± 9 0.036
Systolic blood pressure (mmHg) 132 ± 18 129 ± 16 134 ± 18 134 ± 19 0.001
Diastolic blood pressure (mmHg) 74 ± 9 75 ± 9 73 ± 9 74 ± 10 0.030
HbA1c, %
(mmol/mol)
8.0 ± 1.2 
(64 ± 13)
7.8 ± 1.1
(62 ± 12)
8.1 ± 1.2
(65 ± 13)
8.4 ± 1.2
(68 ± 13) <0.001
Total cholesterol, mmol/l 4.7 ± 0.9 4.7 ± 0.8 4.7 ± 0.9 4.6 ± 1.0 0.360
LDL cholesterol, mmol/l 2.5 ± 0.8 2.5 ± 0.7 2.4 ± 0.8 2.5 ± 0.8 0.639
HDL cholesterol, mmol/l 1.7 ± 0.5 1.8 ± 0.6 1.7 ± 0.5 1.6 ± 0.5 0.001
Triglycerides, mmol/l 1.0 [0.7–1.3] 0.9 [0.7–1.2] 0.9 [0.7–1.4] 1.1 [0.8–1.5] 0.001
eGFR, ml/min/1.73 m2 81 ± 26 92 ± 18 82 ± 23 63 ± 28 <0.001
aUAER, mg/24-h 18 [8–64] 8 [6–12] 33 [17–61] 137 [32–479] <0.001
Retinopathy grade, n (%)
Nil
Simplex
Proliferative
Blind
142 (24)
277 (42)
228 (34)
19 (3)
108 (35)
149 (48)
49 (16)
3 (1)
26 (15)
79 (47)
59 (35)
4 (2)
8 (4)
49 (26)
120 (63)
12 (6)
<0.001
Smokers, n (%) 139 (21) 59 (19) 32 (19) 48 (25) 0.181
RAAS inhibition treatment, n (%) 450 (67) 134 (43) 138 (82) 178 (94) <0.001
Statin treatment (n, %) 401 (60) 129 (41) 113 (68) 158 (84) <0.001
Follow-up
Progression in albuminuria group, n (%) 37 (6) 19 (6) 18 (11) NA NA
Decline in eGFR ≥ 30%, n (%) 93 (14) 10 (3) 19 (11) 64 (34) <0.001
End stage renal disease, n (%) 21 (3) 0 3 (2) 20 (11) <0.001
All-cause mortality, n (%) 58 (9) 12 (4) 21 (13) 25 (13) <0.001
Combined renal endpoint, n (%) 123 (18) 16 (5) 29 (17) 80 (42) <0.001
Table 1. Baseline characteristics according to albuminuria group Data are n (%, rounded), mean ± SD or 
median [IQR]. NA not applicable, UAER urinary albumin excretion rate, RAAS renin-angiotensin-aldosterone 
system. The combined renal endpoint consisted of ≥30% decrease in eGFR from baseline, ESRD and all-cause 
mortality aSome individuals with previous persistent micro- or macroalbuminuria had lower values at baseline 
due to medication.
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Cross-sectional associations of lipid classes with eGFR or albuminuria. In total, 106 known 
lipids from 5 classes (diacyl-phosphatidylcholines (PCs), alkyl-acyl-phosphatidylcholines (PC-Os), 
lyso-phosphatidylcholines (LPCs), triacylglycerols (TGs), and sphingomyelins (SMs)) were identified and 
included in the analyses. The dominance of individual lipid species within their respective lipid classes are listed 
in the Supplementary Report, p. 173–175.
In the cross-sectional analyses, eGFR was inversely associated with SMs and PC-Os, and positively associated 
with PCs and TGs (Fig. 1A). Also, eGFR positively associated with two short-chain LPCs (Supplementary Report, 
p. 37).
Participants in the macroalbuminuria group had lower levels of SMs, PC-Os and medium- length TGs com-
pared to the normo-albuminuria group (Fig. 1B). There were no significant differences between the microalbu-
minuria and normoalbuminuria groups (Supplementary Report, p.17). SM(d40:1), also known as C22:0 SM, and 
SM(d42:1), also known as C24:0 SM, were inversely associated with UAER (Fig. 1C).
Lipid species associated with eGFR or albuminuria slope. PC(36:4) was inversely associated with 
eGFR slope, both, in a crude model (β = -0.013 per 1 SD increase in eGFR; pBH < 0.1; Supplementary Report, p.55) 
and in an adjusted model (β = -0.014; Supplementary Report, p.80). LPC(18:2), seven PC-Os and SM(d18:1/24:0) 
Figure 1. Cross-sectional associations of lipid species and (A) eGFR intervals, (B) macroalbuminuria (n = 189) 
vs. normoalbuminuria (n = 312), and, (C) logUAER. Lipid species are grouped into panels according to the 
lipid classes shown in the title of each panel. Each cell in the heatmap represents one lipid species. On the x-axis 
is number of double-bonds for the specific species (indicating level of unsaturation) and on the y-axis is the 
number of carbon atoms (indicating total fatty acid chain length). The coefficients arise from adjusted logistic 
regression models, individual coefficients are shown in the Supplementary Report, p. 19, 37 and 48. Red colours 
represent positive associations and blue colour negative associations. P-value: #<0.01, x < 0.05 and ≥0.01, 
*<0.1 and ≥0.05, respectively after correction for multiple testing. PC: Phosphatidylcholine, PC-O: alkyl-acyl-
phosphatidylcholine, TG: triglyceride, SM: Sphingomyelin, UAER: urinary albumin excretion rate.
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were all inversely associated with albuminuria slope in a crude model (pBH < 0.1; Supplementary Report, p.63 and 
73). Only LPC(18:2) among these did not remain significant in an adjusted model (Supplementary Report, p.84).
None of the lipid species selected ((p < 0.1) in the adjusted cross-sectional analyses of eGFR) were signifi-
cantly associated to eGFR slope (Supplementary Report, p.76). In the similar analysis involving UACR slope, 
four SMs, PC(O-34:3) and TG(18:0/18:1/20:4) all had significant inverse association to UACR slope (pBH < 0.1; 
Supplementary Report, p.73).
Longitudinal outcomes of renal impairment, ESRD and all-cause mortality. Thirteen lipid species 
significantly associated with either eGFR or albuminuria slope were further analysed using the Cox proportional 
hazards regression models to assess the risk of having at least one renal event (combined renal endpoint). Higher 
levels of three SMs and two PC-Os were associated with lower risk and one TG with higher risk (pBH < 0.1) in 
crude models (Fig. 2A, left). After multivariate adjustment and correction for multiple testing, three sphingo-
myelins were significant as follows (Fig. 2A, right): SM(d38:1), also known as C20:0 SM, (HR (95% CI) 0.39 
(0.23–0.71), pBH = 0.023), SM(d41:1), also known as C23:0 SM (HR 0.49 (0.30–0.79), pBH = 0.042) and SM(d40:1), 
also known as C22:0 SM, (HR 0.43 (0.24–0.77), pBH = 0.053).
When computing HRs for progression in albuminuria group and each of the outcomes included in the com-
bined renal endpoint (Fig. 2B), higher PC-Os and SMs were associated with lower risk of ESRD and all-cause 
mortality in the crude models (pBH < 0.1). Two sphingomyelins (SM(d41:1): HR 0.35 (0.19–0.65), pBH = 0.0040; 
and SM(d40:1): HR 0.33 (0.14–0.75), pBH = 0.032) and PC(O-34:3) (HR 0.47 (0.24–0.92), pBH = 0.083) remained 
significant for all-cause mortality. However, significance for ESRD was lost in the adjusted models.
In addition to the top-ranking lipid species, SM(d41:1), age was also significantly associated with the 
risk of all-cause mortality (Fig. 3A). Association to all-cause mortality was also visually demonstrated in the 
Kaplan-Meier curves of the top and bottom 50% quantiles of SM(d41:1), where individuals with values below the 
median had a higher risk (Fig. 3B). At baseline, the median level of SM(d41:1) in the deceased individuals was 
equal to the 25% quartile in the subjects alive at study end (Fig. 3C).
Similar trends as observed with ESRD and all-cause mortality were present between higher levels of SMs and 
PC-Os and lower risk of ≥30% decline in eGFR or albuminuria group progression. Particularly, SM(d18:1/24:0) 
was associated with albuminuria group progression in the adjusted model (HR: 0.27 (0.09–0.81), pBH = 0.096) 
although this association was not present in the crude model.
Prediction models for all-cause mortality. After performing c-statistics for predictions of all-cause mor-
tality, the area under the curve (AUC) for the model with clinical variables only was 0.77 (0.72–0.80). By adding 
the significant lipid species to the model, the AUC did not improve significantly, AUC 0.79 (0.74–0.81), p = 0.23. 
The relative integrated discrimination improvement (rIDI), between a model including traditional risk factors 
and a model including clinical variables and significant lipid species, however, was 16%, (p = 0.045).
Correlation of lipid species and clinical covariates. In a Spearman correlation matrix including signif-
icant lipid species, clinical covariates and endpoints (Supplementary Report, p.161), strong positive correlations 
were demonstrated between total cholesterol and SMs. Individual SMs were positively correlated as were indi-
vidual PC-Os.
Sensitivity analyses. More extensive models with further adjustments were also computed, including anti-
hypertensive medication, diabetes duration, HDL-C, LDL-C, VLDL-C, as well as technical adjustments for sam-
pling date, analysis batch, and analysis order. These additional adjustments did not significantly influence the 
results, and thus are not shown.
Discussion
We examined serum lipidomic profiles in persons with type 1 diabetes to evaluate potential cross-sectional 
and longitudinal associations with renal function (eGFR) and albuminuria as the clinical features of diabetic 
nephropathy. Additionally, with the follow up information of the cohort we analysed longitudinal associations 
to development of renal impairment, ESRD and mortality. The key findings can be summarized as follows: (1) 
cross-sectional inverse associations of PC-Os and SMs with eGFR, (2) inverse cross-sectional associations of 
PC-Os and SMs with macroalbuminuria, and, (3) in longitudinal analyses, higher levels of specific PC-Os and 
SMs being associated with lower risk of the combined renal endpoint, ESRD and all-cause mortality.
We recognize some limitations in our study. The main limitation is the lack of a replication cohort. Replication 
in an independent cohort would be a requirement for assessing the lipid species as potential biomarkers. Since the 
follow up part of the study was based on available measurements performed at outpatient visits and therefore not 
performed according to a specified protocol, the definition of persistent albuminuria progression may have been 
too conservative. As only one annual assessment of albuminuria was available for many participants, it would 
take longer to develop confirmed progression in albuminuria than if we had three consecutive measurements 
per visit. Since albuminuria has significant day-to-day variation, using a single elevated albuminuria measure-
ment for definition of progression would also not be valid. Data on diet, stress and exercise, which may affect 
the specific lipids17, were not available. Data concerning potential changes in concomitant medication during 
follow-up were not available, and particularly changes in antihypertensive and lipid lowering medication could 
have been relevant. The major strengths of this study are the large population of individuals with type 1 diabetes, 
the well-described comprehensive analyses of lipid species, and, the availability of longitudinal register data for 
up to 7 years.
Overall, there are few comprehensive investigations of global lipidomics in longitudinal studies of 
DN. Many of these studies have focused on both polar and non-polar metabolites (lipids) and most were 
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cross-sectional11–13,15,16. The prior longitudinal studies have primarily focused on albuminuria progression as the 
primary endpoint8,14.
The cross-sectional results demonstrated that PC-Os and SMs were inversely associated with eGFR levels. 
These results seem contradictory to their associations observed with albuminuria, which are also inverse, cross 
sectionally (Fig. 1A,B). The effect sizes, though, were numerically small. However, longitudinally the PC-Os and 
SMs associate negatively with lower eGFR and albuminuria, as expected (Fig. 2B). In the longitudinal analyses, 
one PC specie (PC(36:4)) also demonstrated a significantly positive association with eGFR slope. Part of the 
explanation for these weak and contradictory seeming associations with eGFR (cross-sectionally) may be attrib-
uted to glomerular hyperfiltration, a phenomenon that is often present at the very early stages of DN.
PC-Os and SMs were inversely associated with macroalbuminuria compared to normoalbuminuria in our 
cross sectional analyses whereas a study from Finland by Mäkinen et al., including 326 individuals with type 1 
diabetes, reported higher serum levels of SMs to be associated with presence of macroalbuminuria9. Another 
Finnish study comprising 325 individuals with type 1 diabetes observed higher SMs and lower PC levels asso-
ciated with progression of albuminuria over 8.3 years10. In these Finnish studies, a different platform (proton 
Figure 2. Survival analysis of prioritized lipid species. (A) Lipid species with adjusted p-values < 0.1 in analyses 
of association with eGFR or logUACR slope entered the Cox proportional hazard model for progression to the 
combined renal endpoint consisting of ≥30% decrease in eGFR, ESRD and all-cause mortality with time to 
first event. (B) Significant lipids from the crude model of the combined endpoint are tested for each separate 
endpoint with time to each type of event. HRs are presented per 1 SD increase of the log2 lipid. Adjusted HRs 
(right) controlled for age, sex, HbA1c, systolic blood pressure, smoking, BMI, statin treatment, p-triglycerides, 
total p-cholesterol, eGFR and logUAER. PC phosphatidylcholine, TG triacylglycerol, SM sphingomyelin.
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nuclear magnetic resonance (NMR)) was used, and therefore it may be difficult to compare them to the present 
study. In our study the SMs were positively correlated with total plasma cholesterol levels, as demonstrated in 
the correlation matrix (Supplementary Report, p.161). NMR only quantifies the total SM in contrast to the mul-
tiple SM species measured with the MS. Further, NMR in general measures larger lipid particles, which may 
have higher correlation to total plasma cholesterol levels. Moreover, the participants in the Finnish studies were 
younger and the age difference between the albuminuria groups was larger than in the present study, which could 
contribute to the differing results.
A recent two stage cross-sectional study from Singapore performed in 409 subjects in the discovery and 298 
subjects in the validation cohort analysed both polar and non-polar metabolite levels among individuals with 
type 2 diabetes and varying degrees of diabetic kidney disease16. They observed lower PC and higher long-chain 
SM and ceramide (precursors of sphingolipids) levels associated with a higher degree of albuminuria. Differing 
disease aetiology (type 1 and type 2 diabetes), ethnicity and presumably large dietary (or environmental) differ-
ences could potentially explain the differing results.
In the longitudinal analyses in the present study, higher levels of PC-Os and SMs were associated with lower 
risk of a combined renal endpoint, ESRD and all-cause mortality, although an accurate estimation of adjusted 
HRs would require more events. Moreover, a trend towards higher levels of SMs being associated with progres-
sion in albuminuria status was observed. In a previous study of a subset of 497 individuals with type 1 diabetes 
Figure 3. Survival analysis of SM(d41:1) and clinical covariates for all-cause mortality. (A) Forest plot of 
SM(d41:1) and clinical covariates from multivariate analyses. HRs are presented per 1 SD increase. (B) Kaplan-
Meier curve demonstrating survival probability for levels of SM(d41:1) above (red) and below (blue) the 
median. (C) Distribution of individual SM(d41:1) measurements in a violin plot. Horizontal lines represent the 
median and interquartile ranges. SM Sphingomyelin.
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from the Diabetes Control and Complications Trial, with a follow-up of 14–20 years, lower plasma levels of very 
long chain ceramide species (precursors of sphingolipids)) were also associated with albuminuria progression8. 
Also in line with our findings, a previous case-control study demonstrated lower levels of PCs and other lipid 
species, in 79 subjects who progressed to ESRD, compared to 121 non-progressors, (including 50% with diabetes) 
over 6 years of follow-up18.
The prioritized lipid species that we investigated in the longitudinal models of ESRD and all-cause mortality 
were mostly associated with albuminuria slope. However, these lipids were not associated with eGFR. Albeit albu-
minuria and decline in eGFR are considered markers of glomerular damage, there is growing evidence that albu-
minuria is predominantly of tubular origin (proximal tubule) and somewhat independent of glomerular barrier19.
Although untargeted lipidomics detects a broader panel of lipid species, and we here identified 5 out of 17 
classes (that were seemingly targeted lipidomics), this shows that the current approach may be conservative but 
has undergone robust QC methods (SRM based) reflecting high quality which is next to validation.
In conclusion, altered lipidomic profiles were associated with renal impairment independent of traditional 
markers of kidney function. Higher levels of specific alkyl-acyl-phosphatidylcholines and sphingomyelins spe-
cies were associated with lower risk of ESRD and all-cause mortality, in type 1 diabetes. These results support the 
hypothesis of altered lipid metabolism in renal complications, however, need external validation to assess their 
potential as biomarkers as well as exploration of potential future therapeutic options targeting lipid metabolism.
Methods
Participants. A cohort of 676 individuals with type 1 diabetes followed at Steno Diabetes Center Copenhagen 
between 2009 and 2011 was included in a cross-sectional study and a biobank was created. The selection process 
has previously been described in detail20. The cohort was selected to include individuals within a wide range 
of albuminuria (normo- to macroalbuminuria). Participants were stratified as normoalbuminuric if UAER 
was <30 mg/24 h or mg/g, as microalbuminuric if UAER was or previously had been recorded between 30 and 
299 mg/24 h or mg/g, and as macroalbuminuric if UAER was or previously had been recorded ≥300 mg/24 h or 
mg/g in two out of three consecutive measurements. All subjects classified as normoalbuminuric did not have 
any history of micro- or macroalbuminuria prior to enrolment in the study. Individuals with ESRD defined as 
either receiving dialysis, renal transplantation or having a GFR/ eGFR < 15 mL/min/1.73 m2 were excluded from 
the study.
In the current study, plasma samples from 669 (99%) individuals from the biobank were available for serum 
lipidomics analysis which was performed in 2017.
The study was conducted in accordance with the Declaration of Helsinki. The ethics committee E, Region 
Hovedstaden, Denmark, approved the original as well as the follow-up research study protocol, and all partici-
pants gave a written informed consent.
Study baseline (biochemical and other) measures. UAER was measured at baseline in three consec-
utive 24 h urine collections by enzyme immunoassay (mg/24 h). The eGFR was calculated from serum creatinine 
(determined by an enzymatic method; Hitachi 912; Roche Diagnostics, Mannheim, Germany) using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation21. Information on medication was collected 
from electronic medical records at study baseline.
Lipidomic analyses, data pre-processing and quality control. The serum samples were stored at 
−80 °C until analysis. Samples were prepared and analysed using previously published methods at Steno Diabetes 
Center Copenhagen22,23. The Folch procedure24 was used for sample preparation with minor modifications. 
The samples were analysed using an in-house ultra-high-performance liquid chromatography quadrupole 
time-of-flight mass spectrometry method (UHPLC-QTOF/MS)22,23. The UHPLC system was a 1290 Infinity sys-
tem from Agilent Technologies (Santa Clara, CA, USA). A detailed description is available in the Supplementary 
Methods and a complete list of all identified and included lipids in the Supplementary Report, p.5–7. The lipid-
omics method has been cross-validated in an interlaboratory study including 31 European laboratories that used 
the National Institute of Standards and Technology (NIST) Standard Reference Material (SRM) 1950-Metabolites 
in Frozen Human Plasma25. The lipidomics data were pre-processed with MZmine226. Subsequent quality con-
trol, post-processing and data analysis were done in R. In brief: (1) lipids were semi-quantified by normalizing 
the peak areas to internal standards27; (2) systematic day-to-day variation in the measurements was removed by 
median batch correction28, (3) Lipids with more than 20% missing/undetected values were omitted from subse-
quent analysis; (4) remaining missing values were imputed with the k-nearest neighbour algorithm29; and (5) all 
values were log-2-transformed to achieve normal-distributed data.
Follow-up. All participants were traced through the Danish National Death Register and the Danish National 
Health Register until 31st of December 201630,31. Information was obtained regarding the date and cause of death 
for deceased participants; data on the cause of death was available only until 31st, December 2015. All informa-
tion concerning hospital admission and related international classification of diseases, tenth revision (ICD-10) 
diagnoses (www.who.int/classifications/icd/en/) and procedural codes (according to the Nordic Classification of 
Surgical Procedures; www.sst.dk) were obtained from the Danish National Health Register. Biochemical measure-
ments (p-creatinine (determined by an enzymatic reaction and urinary albumin to creatinine ratio (UACR)) were 
obtained from the local electronic laboratory records. The follow up part of the study was not designed as a clini-
cal trial with measurements of albuminuria on consecutive days, single assessments of albuminuria with differing 
time intervals were available. Data regarding potential changes in medication during follow-up were not available.
Progression in albuminuria status was defined as progression from normo- to microalbuminuria, or micro- 
to macroalbuminuria in at least two out of three consecutive measurements during follow-up. The time of 
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progression was defined as the time of the first elevated measurement. Participants with history of macroalbu-
minuria were excluded from analyses of albuminuria progression. Albuminuria slope was calculated based on all 
the available measurements from outpatient visits during follow-up, in participants with at least 2 measurements 
and a minimum follow-up duration of 3 years (n = 517). Decline in eGFR was assessed as time to the first occur-
rence of ≥30% decrease from baseline, as proposed by Coresh et al.32 and as eGFR slope. ESRD was defined as 
chronic kidney disease stage 5 (ICD-10 code N18.5), chronic dialysis (procedural code BJFD2), kidney transplan-
tation (procedural code KKAS 00, 10 and 20) or eGFR < 15 ml/min/1.73 m2. A combined renal endpoint included 
≥30% decline in eGFR, ESRD and all-cause mortality. The combined endpoint is in line with the hard renal end-
points used in clinical outcome trials, although modified in terms of eGFR decline since this is an observational 
study with no initial decline in eGFR due to intervention. Participants who experienced multiple events were in 
the analyses followed until occurrence of the first event within each outcome.
Statistical analyses. Continuous variables were reported as mean ± SD for normal-distributed data. 
Skewed data were reported as median [interquartile range (IQR)] and were log2-transformed for analyses. 
Categorical variables were presented as total numbers with corresponding percentages. Comparisons of con-
tinuous variables between groups were performed using the ANOVA. The chi-squared test was used to compare 
categorical variables.
Lipid species were tested for association with kidney-related clinical variables and outcomes in a 
narrowing-down approach (Supplementary Fig. s1) as follows: Cross-sectional associations between single lipid 
species and eGFR (15 units and a single category for values above 90 ml/min/1.73 m2), logUAER or albuminu-
ria groups (normo- vs. microalbuminuria and normo- vs. macroalbuminuria) were assessed with linear regres-
sion models adjusted to clinical variables. The adjustment variables were the baseline values of age, BMI, HbA1c, 
p-triglycerides, sex, smoking, statin treatment, systolic blood pressure, total p-cholesterol. Baseline eGFR and 
logUAER, respectively, were also included as adjustments in models, where the investigated association itself 
was not baseline eGFR or logUAER. P-values for each analysis were corrected for multiple testing using the 
Benjamini-Hochberg method (pBH)33,34. Lipid species with pBH < 0.1 in an adjusted cross-sectional model were 
included in longitudinal analyses comprising eGFR and albuminuria (logUACR) slopes. Additionally, longitudi-
nal associations between all lipid species and eGFR and albuminuria slopes were examined under a crude model 
adjusting only for the baseline measure of the outcome variable.
Lipid species associating either in the cross-sectional adjusted model or longitudinal crude model (pBH < 0.1) 
were further tested longitudinally, adjusting for the baseline values of the eleven clinical variables listed above.
Lipids with an association in the longitudinal adjusted model (pBH < 0.1) were further examined using sur-
vival analysis with the Cox proportional hazards model. First, HRs with 95% CI on the log2-scale, were computed 
for the combined renal endpoint, both, in crude and adjusted models. Lipids associating with the combined renal 
endpoint in the crude model (pBH < 0.1) were included for testing of four specific endpoints: albuminuria group 
progression, ≥30% decline in eGFR, ESRD and all-cause mortality.
Finally, the lipid species most significantly associated with all-cause mortality in the adjusted model was inves-
tigated in detail. The survival for participants with lipid levels above or below the median were visualized as 
Kaplan-Meier curves.
Visualizations were done in R (https://www.r-project.org/): Coefficients from lipid-specific linear models were 
visualized as heatmaps. Coefficients of the lipids from survival models were visualized in forest plots grouped by 
the dependent variable. The full forest plot of the model with the top-ranking lipid from the adjusted analysis 
of all-cause mortality was visualized along with the respective Kaplan-Meier curve and outcome-specific violin 
plots. A Spearman correlation matrix including significant lipid species, clinical covariates and endpoints was 
computed. Data analysis was performed with SAS Enterprise Guide version 7.11 and R-3.4.2.
Data availability
Data available on request for researchers who have the relevant legal permissions to access the data.
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